Results 21 to 30 of about 44,840 (262)

Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes.

New England Journal of Medicine, 2020
BACKGROUND Efforts to prevent Clostridioides difficile infection continue to expand across the health care spectrum in the United States. Whether these efforts are reducing the national burden of C. difficile infection is unclear.
A. Guh, Yi Mu, L. Winston, Helen L. Johnston, Danyel M. Olson, M. Farley, L. Wilson, S. Holzbauer, Erin C. Phipps, G. Dumyati, Z. Beldavs, M. Kainer, M. Karlsson, D. Gerding, L. McDonald   +14 more
semanticscholar   +1 more source

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection

JAMA Network Open, 2023
This phase 3, open-label, single-arm trial assesses the safety of SER-109 and the rate of recurrent Clostridioides difficile infection after administration of SER-109 following symptom resolution after antibiotic treatment among adults.
M. Sims, S. Khanna, P. Feuerstadt, T. Louie, C. Kelly, E. Huang, E. Hohmann, E. Wang, C. Oneto, Stuart H. Cohen, C. Berenson, Louis Korman, Christine Lee, B. Lashner, C. Kraft, M. Ramesh, M. Silverman, D. Pardi, A. de, A. Memişoğlu, David A. Lombardi, Brooke R. Hasson, B. McGovern, Lisa von Moltke   +23 more
semanticscholar   +1 more source

ANTIDEPRESSANT MEDICATIONS ARE ASSOCIATED WITH INCREASED RISK OF HOSPITAL-ACQUIRED CLOSTRIDIOIDES DIFFICILE INFECTION: A POPULATION-BASED STUDY [PDF]

Arquivos de Gastroenterologia, 2023
Background: During the past decade, Clostridioides difficile infection (CDI) has become the most common cause of antibiotic-associated diarrhea. Several risk factors have been implicated.
Antoine BOUSTANY, Somtochukwu ONWUZO, Hadi Khaled Abou ZEID, Ashraf ALMOMANI, Imad ASAAD   +4 more
doaj   +1 more source

Analysis of the impact of secondary prophylaxis on recurrence in critically ill adults

SAGE Open Medicine, 2020
Introduction: Clostridioides (formerly Clostridium ) difficile infection recurrence in patients re-exposed to antibiotics for treatment of a non- Clostridioides difficile infection is high at approximately 33%. Low-dose per os vancomycin (e.g. 125 mg q12 
Kathryn A Connor, Kelly M Conn
doaj   +1 more source

Epidemiology of Clostridioides difficile Infections in Germany, 2010–2019: A Review from Four Public Databases

Infectious Diseases and Therapy, 2023
Introduction Clostridioides difficile infection (CDI) is a recognized global threat especially for vulnerable populations. It is of particular concern to healthcare providers as it is found in both hospital and community settings, with severe courses ...
Gordon Brestrich, Frederick J. Angulo, Fabian K. Berger, Christian Brösamle, Stefan Hagel, Andreas Leischker, Christoph Lübbert, Friederike Maechler, Sophie-Susann Merbecks, Nadia Minarovic, Jennifer C. Moïsi, Lutz von Müller, Phillip A. Reuken, Thomas Weinke, Holly Yu, Alexander Mellmann   +15 more
doaj   +1 more source

Rare Clinical Association between Clostridioides difficile Infection and Ischemic Colitis: Case Report and Literature Review

Medicina, 2021
Background and Objectives: Gut microbiota plays an important role in the wellbeing of the host through different interactions between microflora constituents. In certain instances, Clostridioides difficile may pullulate, causing infection with associated
Elena Mirela Ionescu, Ana-Maria Curte, Andrei Ovidiu Olteanu, Carmen Monica Preda, Ioana Tieranu, Artsiom Klimko, Cristian George Tieranu   +6 more
doaj   +1 more source

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial

Clinical Infectious Diseases, 2020
Background Recurrent Clostridioides difficile infection (rCDI) is associated with loss of microbial diversity and microbe-derived secondary bile acids, which inhibit C. difficile germination and growth.
B. McGovern, Christopher B. Ford, M. Henn, D. Pardi, S. Khanna, E. Hohmann, E. O’Brien, C. Desjardins, P. Bernardo, J. Wortman, M. Lombardo, Kevin D Litcofsky, J. Winkler, Christopher McChalicher, Sunny S Li, Amelia Tomlinson, Madhumitha Nandakumar, D. N. Cook, R. Pomerantz, J. Auniņš, M. Trucksis   +20 more
semanticscholar   +1 more source

Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial

BMC Infectious Diseases, 2022
Background Effective treatment options for recurrent Clostridioides difficile infection (rCDI) are limited, with high recurrence rates associated with the current standard of care. Herein we report results from an open-label Phase 2 trial to evaluate the
R. Orenstein, E. Dubberke, S. Khanna, Christine H. Lee, David L. Yoho, Stuart Johnson, G. Hecht, H. Dupont, D. Gerding, Ken F Blount, S. Mische, Adam J Harvey   +11 more
semanticscholar   +1 more source

Clostridioides Difficile Enteritis: Case Report and Literature Review

Antibiotics, 2022
Background: Clostridioides Difficile is a well-known pathogen causing diarrhea of various degrees of severity through associated infectious colitis.
Artsiom Klimko, Cristian George Tieranu, Ana-Maria Curte, Carmen Monica Preda, Ioana Tieranu, Andrei Ovidiu Olteanu, Elena Mirela Ionescu   +6 more
doaj   +1 more source

Insights into the Evolving Epidemiology of Clostridioides difficile Infection and Treatment: A Global Perspective

Antibiotics, 2023
Clostridioides difficile remains an important public health threat, globally. Since the emergence of the hypervirulent strain, ribotype 027, new strains have been reported to cause C.
Crystal Liu, T. Monaghan, Abbas Yadegar, T. Louie, D. Kao   +4 more
semanticscholar   +1 more source